| Title |
A Phase I, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Efficacy of DZD9008 in Chinese Patients with Advanced Non-small Cell Lung Cancer (NSCLC) patients with EGFR or HER2 Mutations |
| Description |
This study includes dose escalation and dose expansion parts. Dose expansion was triggered at dose levels that anti-tumor efficacy was observed in EGFR Exon20ins or HER2 Exon20ins patients. The primary objective is to evaluate safety and tolerability and define MTD and RP2D. |
| Organism |
Homo sapiens |
| Data Type |
Other Type of Genomic Data |
| Data Accessibility |
Controlled-access |
| BioProject |
PRJCA010938 |
| Release Date |
2022-08-03 |
| Submitter |
mengzhao wang (mengzhaowang@sina.com) |
| Organization |
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College |
| Submission Date |
2022-08-02 |